Anavex Life Sciences Corp. Stock News

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeut

AVXL earnings call for the period ending March 31, 2022.

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President &

Company to host a webcast today at 4:30 p.m. Eastern Time

Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape

In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies

Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptors. Simufilam may do the same.

Anavex Life Sciences Corp (NASDAQ: AVXL ) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson''s Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for patients treated with … Full story available on Benzinga.com

NEW YORK , March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, AVXL, AAL, GTLB, and SABR. … Full story available on Benzinga.com

Anavex Life Sciences Corp (NASDAQ: AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 Int

On Tuesday, Anavex Life Sciences (AVXL), a clinical-stage biotech focused on treatment for CNS disorders, announced Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001…

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Medallion Financial Corp. (NASDAQ: MFIN), Clariant AG (OTCMKTS: CLZNY), and Anavex Life Sciences Corp. (NASDAQ: AXVL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated thera